143 related articles for article (PubMed ID: 37357301)
41. Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores.
Williams MM; Storandt M; Roe CM; Morris JC
Alzheimers Dement; 2013 Feb; 9(1 Suppl):S39-44. PubMed ID: 22858530
[TBL] [Abstract][Full Text] [Related]
42. Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.
Muralidharan KK; Kowalski KG; Tong X; Haeberlein SB; Rajagovindan R; Nestorov I
J Pharmacokinet Pharmacodyn; 2023 Feb; 50(1):45-62. PubMed ID: 36600109
[TBL] [Abstract][Full Text] [Related]
43. Predicting the time to clinically worsening in mild cognitive impairment patients and its utility in clinical trial design by modeling a longitudinal clinical dementia rating sum of boxes from the ADNI database.
Ito K; Hutmacher MM
J Alzheimers Dis; 2014; 40(4):967-79. PubMed ID: 24531162
[TBL] [Abstract][Full Text] [Related]
44. Validity of the Clinical Dementia Rating Scale Sum of Boxes in Staging and Detection of Cognitive Impairment in Mexican Americans.
Julayanont P; DeToledo JC
J Geriatr Psychiatry Neurol; 2022 Jan; 35(1):128-134. PubMed ID: 33261535
[TBL] [Abstract][Full Text] [Related]
45. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
[TBL] [Abstract][Full Text] [Related]
46. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
[TBL] [Abstract][Full Text] [Related]
47. Donanemab in early symptomatic Alzheimer's disease.
Drug Ther Bull; 2024 Apr; 62(5):67. PubMed ID: 38580400
[No Abstract] [Full Text] [Related]
48. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
[TBL] [Abstract][Full Text] [Related]
49. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
50. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
[TBL] [Abstract][Full Text] [Related]
51. Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Mazer NA; Hofmann C; Lott D; Gieschke R; Klein G; Boess F; Grimm HP; Kerchner GA; Baudler-Klein M; Smith J; Doody RS;
Alzheimers Dement; 2023 Jun; 19(6):2287-2297. PubMed ID: 36454709
[TBL] [Abstract][Full Text] [Related]
52. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
[TBL] [Abstract][Full Text] [Related]
53. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
[TBL] [Abstract][Full Text] [Related]
54. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
[TBL] [Abstract][Full Text] [Related]
55. Souvenaid for Alzheimer's disease.
Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
[TBL] [Abstract][Full Text] [Related]
56. Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials.
Rashad A; Rasool A; Shaheryar M; Sarfraz A; Sarfraz Z; Robles-Velasco K; Cherrez-Ojeda I
Healthcare (Basel); 2022 Dec; 11(1):. PubMed ID: 36611492
[TBL] [Abstract][Full Text] [Related]
57. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
58. How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?
Gauthier S; Leuzy A; Rosa-Neto P
Neurodegener Dis; 2014; 13(2-3):197-9. PubMed ID: 23942173
[TBL] [Abstract][Full Text] [Related]
59. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2012 May; 5(5):CD005380. PubMed ID: 22592705
[TBL] [Abstract][Full Text] [Related]
60. Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions.
Voss T; Kost J; Mercer SP; Furtek C; Randolph C; Lines C; Egan MF; Cummings JL
J Alzheimers Dis; 2023; 92(1):341-348. PubMed ID: 36744336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]